<DOC>
	<DOCNO>NCT02179918</DOCNO>
	<brief_summary>This safety , pharmacokinetic pharmacodynamic study design estimate maximum tolerate dose ( MTD ) , determine Recommended Phase 2 Dose ( RP2D ) PF-05082566 , 4-1BB agonist monoclonal antibody ( mAb ) , combination MK-3475 , PD-1 inhibitor patient solid tumor .</brief_summary>
	<brief_title>A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors ( B1641003/KEYNOTE-0036 )</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Histological cytological diagnosis advanced/metastatic solid tumor malignancy progress standard therapy standard therapy available . Measurable disease per RECIST v1.1 . Adequate bone marrow , renal liver function CNS primary malignancy , active seizure disorder spinal cord compression , carcinomatous meningitis . History follow toxicity associate prior immunotherapy : Grade 3 immune mediate adverse event consider related previous immunotherapy require immune suppressive therapy ; Grade 2 hepatic function relate adverse event persist 1 week , consider related immunotherapy , require treatment discontinuation immunosuppressive therapy Any follow within 12 month prior registration : myocardial infarction , uncontrolled angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack 6 month deep vein thrombosis pulmonary embolism . History know presence extensive , disseminated/bilateral Grade 3 4 interstitial fibrosis interstitial lung disease , include history pneumonitis , hypersensitivity pneumonitis , interstitial pneumonia , interstitial lung disease , obliterative bronchiolitis , pulmonary fibrosis , include history prior radiation pneumonitis . Patients clinically significant lung disease require oxygen therapy ( eg , COPD ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced Solid Tumors</keyword>
</DOC>